A morning blood draw, not a questionnaire, may end up being the clearest signal that ketamine is working. Researchers studying the drug’s rapid effect on suicidal thoughts have found that patients who respond best show a distinct hormonal fingerprint the next day: a sharp rise in cortisol that is still measurable a full 24 hours after treatment.
For a hormone usually blamed for anxiety, poor sleep and burnout, that is a strange thing to celebrate. But in this context, cortisol looks less like a symptom of distress and more like a signature of the brain resetting itself.
A stress hormone playing an unexpected role
Cortisol follows a predictable daily rhythm in healthy people. Levels rise sharply in the first 30 to 45 minutes after waking, a pattern researchers call the cortisol awakening response, then decline steadily through the day.
In major depression, that rhythm is frequently blunted or flattened, one of the more consistent biological findings in mood disorder research over the past two decades. The new observation is that a single ketamine infusion appears to restore, and even amplify, that morning surge.
The size of the increase tracks with how much a patient’s suicidal ideation drops in the following day. Patients with the steepest overnight cortisol climb tended to report the steepest drop in suicidal thinking, suggesting the two are mechanistically linked rather than coincidental.
That persistence matters. Ketamine itself clears from the bloodstream within hours, yet its antidepressant and anti-suicidal effects are well documented to outlast the drug by days.
A hormonal change still present a full day later offers one of the first physiological explanations for why the psychological benefit doesn’t evaporate along with the drug.
How ketamine acts on the brain
Ketamine’s psychiatric use grew out of its ability to block NMDA receptors, a class of glutamate receptors central to how neurons communicate and rewire in response to experience. That blockade triggers a rebound surge in glutamate signaling through a different receptor type, AMPA receptors.
Researchers believe this drives a rapid burst of new synaptic connections in mood-regulating circuits of the prefrontal cortex. This mechanism was first demonstrated in animal models and later confirmed in human trials showing relief within hours rather than the weeks typical of standard antidepressants.
What has remained unclear is why the effect fades for some patients within days while others stay well for weeks. Cortisol may be part of that answer.
The hypothalamic-pituitary-adrenal axis, the body’s central stress-response system, doesn’t just react to threats. It also interacts directly with brain-derived neurotrophic factor and synaptic plasticity pathways, the same systems implicated in ketamine’s antidepressant action.
A short, well-timed cortisol pulse can support the kind of neural remodeling that chronic, dysregulated stress normally undermines.
Timing appears to be the whole story
The distinction researchers are drawing is not simply more cortisol versus less. It’s when the rise happens.
A flattened morning peak is a hallmark of depression and chronic stress, while a chronically elevated, all-day cortisol level is linked to anxiety, poor sleep and metabolic harm. What this research describes is a temporary, well-timed morning spike layered on top of an otherwise normal rhythm.
That pattern looks biologically closer to a healthy stress response reactivating than to a stress overload building up. Context, dose and timing determine whether cortisol helps or hurts, and here it resembles the body’s own resilience system switching back on.
A field built on unexpected findings
Ketamine’s psychiatric story has always moved through accidents and reversals. It began as a battlefield anesthetic in the 1960s, resurfaced as a party drug flagged for abuse potential in the 1980s and 1990s, then re-emerged as one of the most closely studied psychiatric treatments of the last twenty years.
John Krystal and colleagues at Yale University documented ketamine’s rapid mood effects in the 1990s, work that helped launch the modern research field. Ronald Duman, also at Yale, spent much of his career mapping how the drug triggers synaptic growth through brain-derived neurotrophic factor and the mTOR signaling pathway.
That research helped explain why a single infusion could do in hours what weeks of standard antidepressants often fail to achieve. Cortisol’s arrival in this story fits an established pattern: a hormone once treated purely as a marker of damage turning out to carry information about repair.
Sleep and stress researchers made a similar discovery with the cortisol awakening response itself decades ago, finding that its size, not its mere presence, reflects how well someone’s stress-regulation system is functioning. Applying that same lens to psychiatric treatment response is a logical, if overdue, next step.
What this doesn’t mean
This is not a case for chasing cortisol on your own. Ketamine used for suicidal ideation is administered as a controlled intravenous or intranasal treatment under direct medical supervision, typically in a clinic equipped to monitor blood pressure, heart rate and dissociative side effects during the infusion.
Cortisol itself is not the treatment. It appears to be a downstream marker of a much more complex neurochemical cascade.
Elevating cortisol through unrelated means, such as stress, poor sleep or stimulants, would not be expected to reproduce this effect and could plausibly make depression symptoms worse. Anyone experiencing suicidal thoughts should reach out to a crisis line or mental health professional rather than treat this research as a self-directed strategy.
Toward a same-day biomarker
If the cortisol link holds up in larger trials, it could solve a genuine problem in psychiatric care: knowing whether a treatment worked before the crisis window has passed. Clinicians currently rely on symptom questionnaires administered days after treatment, a lag that offers little help when the priority is same-day safety.
A blood draw the following morning that reliably predicts response could let clinicians identify who needs closer monitoring or a second intervention almost immediately, rather than waiting to see if symptoms return. That would mark a meaningful shift for a field that has spent decades searching for objective biomarkers to replace subjective mood ratings.
Depression and suicidal ideation remain diagnosed and tracked almost entirely through what patients report feeling, an approach that is inherently delayed and colored by the difficulty many people have describing their own mental state accurately. A measurable, physical signal tied directly to symptom change would not replace clinical judgment.
None of this makes suicidal ideation simple, and no single hormone will ever fully explain why one person recovers quickly and another doesn’t. But for a field that has spent so long treating the days after a crisis as a waiting period, a measurable signal on the very next morning is not a small thing.
It is the difference between hoping a treatment worked and having a reason to believe it did.
